Targeting the liver serine protease TMPRSS6 ameliorates steatosis and attenuates fibrosis in experimental MASLD
Targeting the liver serine protease TMPRSS6 ameliorates steatosis and attenuates fibrosis in experimental MASLD
Two days after the last injection mice were sacrificed and liver was extracted for molecular analysis  C57BL/6J male mice (eight-week-old) were purchased from Envigo, fed a fructose-palmitate cholosterol (FPC) diet (SSNIFF #S1102-E712) or a control diet (SSNIFF #S1102-E714) for 12 weeks, and then treated twice a week for six weeks with triantennary N-acetyl galactosamine (GalNAc)-conjugated antisense oligonucleotide (ASO) against Tmprss6 or a non-targeting control ASO  Total RNA was extracted from liver using TRIFAST (Euroclone) according to manufacturers instruction.  mRNA-Seq libraries were created according to the standard Illumina TruSeq protocol.